Novartis India surges 51% on Pfizer trademark acquisition deal

Novartis India's share price climbed 51 per cent over a three-day trading period, driven by the company's announcement that it has acquired the Minipress and Minipres trademarks along with associated intellectual property rights from Pfizer Inc and Pfizer Products Inc.

The transaction, valued at ₹1,250 crore, represents a significant expansion of Novartis India's portfolio in the Indian pharmaceutical market. The Minipress and Minipres brands are well-established medications, and acquiring the trademarks positions Novartis to strengthen its presence in this therapeutic segment.

The sharp appreciation in the stock price reflects investor enthusiasm for the strategic acquisition. Market analysts view the deal as a positive development for Novartis India's growth trajectory, as it adds established, revenue-generating brands to the company's existing product basket.

The acquisition underscores the active consolidation activity in India's pharmaceutical sector, where companies continue to pursue strategic deals to enhance their market positioning and diversify their therapeutic offerings. For Novartis India, the move represents an opportunity to leverage existing distribution networks and manufacturing capabilities to maximise the commercial potential of the acquired assets.